Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 881 participants.

Also called NCT01819129

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 881 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01819129
  • EudraCT 2010-024051-93
  • CTRI CTRI/2014/01/004285
Main results
  • Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial Diabetes care, 2017-07 DOI, PubMed 28483786

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Croatia, India, Israel, Puerto Rico, Russia, Serbia, Slovakia, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01819129. Randomized; double masking; primary purpose treatment. Start 2013-09-09 (actual); primary completion 2015-01-22 (actual). Results posted on 2017-12-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
Acronym
onset® 2
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Faster-acting insulin aspart
Intervention (Drug)
Insulin aspart
Intervention (Drug)
Insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01819129
Content hash
d0565dc4a18db0de27fc17bcb65d03e917bd8e896202d436cd162039512c990e